Cancer Pharmacology Publications - 2006

Refereed Journal Articles

Aggarwal G, Glare P, Clarke S, Chapuis P. Palliative and shared care concepts in patients with advanced colorectal cancer. Australia and New Zealand Journal of Surgery 76: 175-180, 2006.

Goldstein D, Mitchell P, Michael M, Beale P, Friedlander M, Zalcberg J, White S, Clarke S. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients. British journal of cancer 92: 832-837, 2005.

Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clinical cancer research 12: 7492-7497, 2006.

Charles KA, Rivory LP, Stockler MR, Beale P, Beith J, Boyer M, Clarke SJ. Predicting the toxicity of weekly docetaxel in advanced cancer. Clinical pharmacokinetics 45: 611-622, 2006.

Clarke SJ, Boyer MJ, Millward M, Underhill C, Moylan E, Yip D, White S, Childs A, Beale P, Latz J, Suri A, Iglesias JL. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 49: 401-412, 2005.

Joshua AM, Adams D, McKenzie P, Solomon M, Clarke SJ. Small blue cell tumors of the rectum. Case 2. Small-cell carcinoma of the rectum. Journal of Clinical Oncology 23: 912-913, 2005.

Joshua AM, Boyer MJ, Subramanian R, Clarke SJ. Smoking reduction does work: resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years. Respirology 10: 233-238, 2005.

Joshua AM, Cotroneo A, Clarke S. Humor and oncology. Journal of Clinical Oncology 23: 645-648, 2005.

Joshua AM, Nordman I, Venkataswaran R, Clarke S, Stockler MR, Boyer MJ. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer. Internal medicine journal 35: 468-472, 2005.

Joshua AM, Nordman I, Venkatawaran R, Stockler M, Boyer M, Clarke S. Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC). Journal of Clinical Oncology 23: 431S-431S, 2005.

Li KM, Rivory LP, Clarke SJ. Rapid quantitation of plasma 2'-deoxyuridine by high-performance liquid chromatography/atmospheric pressure chemical ionization mass spectrometry and its application to pharmacodynamic studies in cancer patients. Journal of chromatography B, Analytical technologies in the biomedical and life sciences 820: 121-130, 2005.

Li KM, Rivory LP, Clarke SJ. Solid-phase extraction (SPE) techniques for sample preparation in clinical and pharmaceutical analysis: A brief overview. Current Pharmaceutical Analysis 2: 95-102, 2006.

Li KM, Rivory LP, Hoskins J, Sharma R, Clarke SJ. Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients. British journal of clinical pharmacology, 2006.

Nordman IC, Iyer S, Joshua AM, Clarke SJ. Advances in the adjuvant treatment of colorectal cancer. Australia and New Zealand Journal of Surgery 76: 373-380, 2006.

Michael M, Thompson M, Hicks RJ, Mitchell PL, Ellis A, Milner AD, Di Iulio J, Scott AM, Gurtler V, Hoskins JM, Clarke SJ, Tebbut NC, Foo K, Jefford M, Zalcberg JR. Relationship of hepatic functional imaging to irinotecan pharmacokinetics and genetic parameters of drug elimination. Journal of Clinical Oncology 24: 4228-4235, 2006.

Mitchell P, Goldstein D, Michael M, Beale P, Friedlander M, Zalcberg J, Clarke S, White S. Addition of gabapentin (G) to a modified FOLFOX regimen does not reduce neurotoxicity in patients (pts) with advanced colorectal cancer (CRC). Journal of Clinical Oncology 23: 266S-266S, 2005.

Read JA, Beale PJ, Horvath LG, Volker D, Childs A, Smith N, Clarke SJ. Impact of fish-oil supplement on nutritional parameters, inflammation and chemotherapy induced toxicity in colorectal cancer (CRC) patients receiving FOLFIRI - A pilot study. Journal of Clinical Oncology 23: 789S-789S, 2005.

Read JA, Crockett N, Volker DH, MacLennan P, Choy STB, Beale P, Clarke SJ. Nutritional assessment in cancer: comparing the Mini-Nutritional Assessment (MNA) with the scored Patient-Generated Subjective Global Assessment (PGSGA). Nutrition and cancer 53: 51-56, 2005.

Sharma R, Boyer M, Clarke S, Millward M. Gefitinib in advanced non-small cell lung cancer. Internal medicine journal 35: 77-82, 2005.

Sharma R, McLeod D, Clarke SJ. Small blue cell tumors of the rectum. Case 3. Atypical carcinoid of the rectum. Journal of Clinical Oncology 23: 914-915, 2005.

Sharma R, Rivory L, Beale P, Ong S, Horvath L, Clarke SJ. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. British journal of cancer 94: 964-968, 2006.

Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncology 6: 93-102, 2005.

Sharpe L, Butow P, Smith C, McConnell D, Clarke S. Changes in quality of life in patients with advanced cancer: evidence of response shift and response restriction. Journal of psychosomatic research 58: 497-504, 2005.

Sharpe L, Butow P, Smith C, McConnell D, Clarke S. The relationship between available support, unmet needs and caregiver burden in patients with advanced cancer and their carers. Psycho-Oncology 14: 102-114, 2005.

Stockler MR, Tattersall MHN, Boyer MJ, Clarke SJ, Beale PJ, Simes RJ. Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. British journal of cancer 94: 208-212, 2006.

Su GM, Fiala-Beer E, Weber J, Jahn D, Robertson GR, Murray M. Pretranslational upregulation of microsomal CYP4A in rat liver by intake of a high-sucrose, lipid-devoid diet containing orotic acid. Biochemical pharmacology 69: 709-717, 2005.

Tobin P, Clarke S, Seale JP, Lee S, Solomon M, Aulds S, Crawford M, Gallagher J, Eyers T, Rivory L. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. British journal of clinical pharmacology 62: 122-129, 2006.

Tobin PJ, Beale P, Noney L, Liddell S, Rivory LP, Clarke S. A pilot study on the safety of combining chrysin, a non-absorbable inducer of UGT1A1, and irinotecan (CPT-11) to treat metastatic colorectal cancer. Cancer chemotherapy and pharmacology 57: 309-316, 2006.

Tobin PJ, Seale P, Lee S, Solomon M, Fields S, Rivory L, Clarke S. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours. Journal of Clinical Oncology 23: 283S-283S, 2005.

Trevena LJ, Sainsbury P, Henderson-Smart C, Clarke R, Rubin G, Cumming R. Population health integration within a medical curriculum: an eight-part toolkit. American journal of preventive medicine 29: 234-239, 2005.

Vardy J Clarke SJ. Ewing''s sarcoma of the rectum: Are four cycles of chemotherapy enough? Reply. Journal of Clinical Oncology 23: 5850-5850, 2005.

Vardy J, Joshua AM, Clarke SJ, Yarrow PM, Lin BPC. Small blue cell tumors of the rectum. Case 1. Ewing's sarcoma of the rectum. Journal of Clinical Oncology 23: 910-912, 2005